Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 1-myristoylglycerophosphocholine: Precision Tool for Lipid M

    2026-07-08

    1-myristoylglycerophosphocholine: Precision Tool for Lipid Metabolism Research

    Introduction: The Evolving Role of 1-myristoylglycerophosphocholine in Biomedical Research

    Lipid signaling molecules have emerged as central regulators in diverse biological processes, from membrane dynamics to disease progression. Among them, 1-myristoylglycerophosphocholine (14:0 Lyso-PC) stands out as a structurally well-defined lysophospholipid, uniquely suited to dissect the mechanisms underlying smooth muscle contraction, cellular signaling, and pathological remodeling. Unlike generic overviews found in prior guides, this article delivers a comprehensive examination of the molecular actions, research applications, and assay design considerations for 1-myristoylglycerophosphocholine, anchored in recent discoveries that reshape our understanding of lipid-driven disease mechanisms.

    Molecular Properties and Mechanistic Insights

    1-myristoylglycerophosphocholine (CAS No. 20559-16-4) is a monoglycerophospholipid characterized by a myristoyl (14:0) fatty acid at the sn-1 position of the glycerol backbone and a phosphorylcholine head group. This configuration renders it a potent mediator of lysophospholipid-sensitive receptor signaling. In vivo, it is primarily generated in plasma through the action of lecithin:cholesterol acyltransferase during lipid remodeling, but researchers can now employ the purified compound to manipulate signaling pathways with high specificity and reproducibility in vitro.

    Bioactivity Profile

    Functionally, 1-myristoylglycerophosphocholine modulates downstream pathways by acting as a ligand for cellular receptors sensitive to lysophospholipids. Its effects are evident at nanomolar to micromolar concentrations, with experimental outcomes dependent on the cellular context and assay system. Notably, it is widely used to study the regulation of enzyme activity, signal transduction, and the pharmacology of smooth muscle contraction and relaxation, where it has demonstrated reliable antispasmodic effects (see recent assay-focused discussions for practical perspectives).

    Mechanism of Action of 1-myristoylglycerophosphocholine

    At the cellular level, 1-myristoylglycerophosphocholine, as a representative Lyso-PC species, interacts with G protein-coupled and other lysophospholipid-sensitive receptors. This triggers signaling cascades that can regulate calcium influx, modulate kinase activity, and ultimately alter smooth muscle tone. The antispasmodic actions observed in muscle function research reflect its capacity to disrupt contractile signaling, making it a valuable probe for dissecting both physiological and pathological contractile responses.

    Moreover, its role as a lipid signaling mediator extends to the modulation of inflammatory responses and membrane organization, positioning it as a versatile tool for studying the interface of cell signaling and disease biology.

    Translational Insights from Recent Breakthroughs in Lipid Metabolism

    Reference Insight Extraction: HMGCS2, Lyso-PC, and Fibrosis Progression

    A pivotal study by Yang et al. (Respiratory Research, 2024) has redefined the landscape of lysophospholipid research by unraveling the connection between epithelial lipid metabolism, Lyso-PC accumulation, and fibrosis. The authors demonstrated that downregulation of HMGCS2 in type II alveolar epithelial cells (AECIIs) leads to aberrant lipid accumulation—most notably Lyso-PCs—which can then activate fibroblasts and promote pulmonary fibrosis. This mechanism was elucidated using untargeted lipidomics, cell-based assays, and in vivo models, providing robust evidence that Lyso-PCs are not mere biomarkers but active drivers of disease progression. For experimentalists, this finding underscores the importance of choosing Lyso-PC analogs like 1-myristoylglycerophosphocholine with defined chain lengths and head groups for mechanistic studies and pathway-specific interventions.

    Practically, the study guides researchers to leverage 1-myristoylglycerophosphocholine in the reconstruction of disease-relevant signaling environments—whether modeling fibrosis, exploring smooth muscle contractility, or dissecting the inflammatory cascade—by mimicking the lipid signals implicated in pathological remodeling.

    Comparative Analysis with Alternative Methods

    Unlike broader approaches that employ undefined lipid mixtures or crude extracts, the use of chemically pure 1-myristoylglycerophosphocholine enables precise manipulation of receptor-ligand interactions and downstream pathway activation. Prior resources, such as the workflow-oriented "1-myristoylglycerophosphocholine in Lipid Signaling Assays", emphasize troubleshooting and practical workflows. This article extends those insights by focusing on the molecular rationale for selecting defined Lyso-PC species, the scientific consequences of chain length variation, and the implications for experimental reproducibility and translational relevance.

    For researchers seeking to model disease mechanisms with greater fidelity, the specificity offered by 1-myristoylglycerophosphocholine is a crucial advantage. It allows for the deconvolution of lipid signaling events and the design of targeted interventions in both cell-based and physiological systems.

    Advanced Applications: From Smooth Muscle to Fibrosis and Inflammation

    The versatility of 1-myristoylglycerophosphocholine enables its use across multiple research domains:

    • Smooth muscle contraction and relaxation: As a selective lysophospholipid, it modulates contractile signaling in isolated tissue and cellular models. Its antispasmodic effects are leveraged to probe the pharmacology of muscle tone regulation and to screen for modulatory compounds.
    • Lipid signaling pathway analysis: The defined structure of 1-myristoylglycerophosphocholine makes it ideal for dissecting receptor-mediated events, kinase activation, and downstream gene regulation in lipid signaling networks.
    • Inflammation mechanism research: By mimicking endogenous Lyso-PC signaling, researchers can model inflammatory cascades and explore the crosstalk between lipid mediators and immune effectors.
    • Fibrosis modeling: In light of the recent mechanistic link between Lyso-PCs and fibroblast activation, this compound is particularly valuable for reconstructing disease-relevant microenvironments and evaluating anti-fibrotic strategies (as discussed in HMGCS2 Downregulation Drives Lyso-PC–Mediated Pulmonary Fibrosis). Our present article builds upon such findings by providing actionable guidance on how to use defined Lyso-PCs for hypothesis-driven experimental design, rather than focusing solely on pathway analysis or troubleshooting tips.

    Protocol Parameters

    • Concentration ranges: For cell-based assays, 1-myristoylglycerophosphocholine is effective from low nanomolar (10–100 nM) to low micromolar (0.5–5 μM) concentrations, depending on cell type and endpoint.
    • Solubility guidance: The compound is insoluble in DMSO but dissolves readily in ethanol (≥13.4 mg/mL with ultrasonication) and water (≥24.75 mg/mL). Prepare fresh solutions before use, as prolonged storage is not recommended (manufacturer's specifications).
    • Storage: Solid product should be kept at -20°C. Use solutions immediately; avoid freeze-thaw cycles.
    • Tissue model application: For smooth muscle studies, pre-incubate tissues with the compound for 10–30 minutes prior to contractile agent addition.
    • Fibroblast activation models: Treat fibroblast cultures with 1–5 μM for 24–48 hours to induce activation markers, as suggested by lipidomics-driven models.

    Why This Perspective Matters: Differentiating from Existing Content

    While prior articles such as "Precision Tools for Lipid Signaling Assays" have centered on assay optimization and translational relevance, the focus here is on integrating the latest mechanistic discoveries—most notably the role of HMGCS2 and Lyso-PC in fibrosis progression—into the selection and application of defined research compounds. This approach not only enhances scientific rigor but also supports the design of pathway-specific experiments that can inform both basic research and therapeutic development. Our article prioritizes the translational bridge between molecular mechanism and practical assay design, using APExBIO's high-purity 1-myristoylglycerophosphocholine as the model compound of choice.

    Conclusion and Future Outlook

    The advent of defined lysophospholipid reagents such as 1-myristoylglycerophosphocholine empowers researchers to interrogate lipid signaling with unprecedented precision. The recent elucidation of Lyso-PC’s pathogenic role in pulmonary fibrosis—mediated by HMGCS2 downregulation and epithelial lipid remodeling—underscores the necessity of using structurally specific lipid mediators in both mechanistic and translational research. By leveraging well-characterized compounds and integrating insights from cutting-edge studies, scientists can more effectively design experiments that bridge the gap between molecular signaling and disease intervention.

    Looking forward, the continued refinement of lipidomics, single-cell technologies, and receptor profiling will further enhance the utility of 1-myristoylglycerophosphocholine in disease modeling and drug discovery pipelines. However, the field must remain attentive to chain length specificity, receptor selectivity, and cellular context—parameters best addressed by using rigorously defined compounds from trusted suppliers like APExBIO.